Avadel, Lumryz
Avadel Gets Expanded FDA OK of Lumryz for Use in Children
Avadel Pharmaceuticals has won expanded Food and Drug Administration approval of its narcolepsy drug Lumryz for use in children. Avadel on Thursday said the FDA nod covers Lumryz for the treatment of cataplexy, or excessive daytime sleepiness, in children ages seven and older with narcolepsy, a chronic sleep disorder.
Avadel's drug contains a central nervous system depressant drug called sodium oxybate, which helps increase the amount of ...
Avadel Pharmaceuticals said its once-nightly narcolepsy drug Lumryz can now be used to treat children older than 7 years of ...
Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...
Cetera Investment Advisers trimmed its position in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 5.4% during the second quarter, according to the company in its most recent 13F filing with ...
(RTTNews) - Avadel Pharmaceuticals plc (AVDL), Tuesday revealed that 94 percent of patients in RESTORE study with narcolepsy preferred the once-nightly regimen of Lumryz over twice-nightly Oxybate ...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) reported better-than-expected fourth-quarter revenue results and also issued a corporate update on Monday.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback